CardiologyValvular Heart Disease

Mitral Regurgitation

Mitral regurgitation is the backward leakage of blood from the left ventricle into the left atrium during systole due to incompetent closure of the mitral valve.

Exam domainOne-glance essentials
Definition / diagnosis
  • Systolic backflow from LV→LA due to failure of leaflet coaptation [1][2]
  • Primary MR: intrinsic leaflet/chordal/papillary-muscle lesion; secondary MR: structurally normal leaflets pulled apart by ventricular or atrial remodelling [1][4]
  • Acute and chronic MR differ sharply because the chronic LA/LV can remodel to accommodate regurgitant volume [2]
Epidemiology / risks
  • Primary: degenerative prolapse/flail, chordal rupture, endocarditis, rheumatic disease, or connective-tissue disorder [1][2]
  • Secondary: ischaemic LV remodelling, dilated cardiomyopathy, or atrial/annular dilatation from long-standing AF [1][4]
  • Posteromedial papillary muscle rupture is the classic post-MI lesion because it usually has a single PDA blood supply [2]
Core mechanism
  • Chronic regurgitant volume → LA + eccentric LV dilatation → initially preserved total stroke volume but eventual LV dysfunction and pulmonary hypertension [2]
  • Acute MR into a small, non-compliant LA → abrupt LA pressure rise with giant v waves → flash pulmonary oedema and shock [2]
  • Secondary MR is a ventricular/atrial disease, so reverse remodelling can reduce the leak [4]
Clinical picture
  • Chronic: exertional dyspnoea, fatigue, palpitations/AF, displaced hyperdynamic apex, and soft S1 [2]
  • High-pitched pansystolic apical murmur radiating to the axilla; handgrip usually increases it [2]
  • Acute severe MR: sudden pulmonary oedema, hypotension/shock; the murmur may be short or soft [2]
Investigations
  • TTE is first line: identify mechanism, integrate MR severity, and measure LV/LA size, LVEF, pulmonary pressure, RV function, and concomitant TR [1][4]
  • 3D TOE defines leaflet segments/coaptation and repairability, and is central to surgical or transcatheter planning [1][4]
  • A discordance between symptoms and resting MR severity may need exercise echo, CMR quantification, or invasive confirmation [4]
Management
  • Acute severe MR is a surgical emergency: oxygen/ventilation, diuretic, afterload reduction if BP allows, and mechanical/inotropic support are bridges to urgent repair/replacement [1][2]
  • Severe primary MR: repair is preferred when durable; intervene for symptoms or LV trigger—LVEF ≤60%, LVESD ≥40 mm, or LVESDi ≥20 mm/m² [1][4]
  • Severe secondary MR: first optimise HF GDMT ± CRT/revascularisation; consider TEER or surgery only after Heart Team reassessment [4]
Complications
  • AF, systemic embolism, pulmonary hypertension, progressive LV failure, right-heart failure, and infective endocarditis [1][2]
  • Acute papillary-muscle/chordal rupture → flash pulmonary oedema and cardiogenic shock [1][2]
  • Severe LA enlargement may cause Ortner syndrome from recurrent laryngeal-nerve compression [2]
Prevention / follow-up
  • Serial echo must detect silent LV dysfunction before symptoms; severe asymptomatic primary MR belongs in a Heart Valve Centre when repair is likely [4]
  • Treat hypertension, ischaemia, HF, and AF; good dental hygiene reduces bacteraemia, but native MR alone does not justify routine antibiotic prophylaxis [2][4]
  • After repair/replacement, continue structured valve surveillance and antithrombotic therapy appropriate to the procedure [4]
Exam traps
  • LVEF 60% is already abnormal in severe MR: regurgitation makes LV ejection deceptively easy, so a seemingly ‘normal’ EF can mask contractile failure [2][4]
  • Soft murmur does not exclude acute severe MR—rapid LA/LV pressure equalisation can shorten the murmur [2]
  • Medication may treat congestion or the diseased ventricle, but it does not repair primary MR; durable valve repair is preferred when feasible [1]

References

[1] Lecture slides: Cardiac Surgery Tutorial_Prof. D Chan.pdf (pp. 36, 38–39, 43, 46, 56, MR mechanism, investigation, repair, and surgery) [2] Senior notes: Ryan Ho Cardiology.pdf (pp. 154–157, mitral regurgitation); Maksim Medicine Notes.pdf (pp. 35–39, valvular disease and endocarditis) [4] Guideline: 2025 ESC/EACTS Guidelines for the management of valvular heart disease (section 9, mitral regurgitation)

Mitral Regurgitation (MR)

Mitral regurgitation (MR) is the backward leakage of blood from the left ventricle (LV) into the left atrium (LA) during systole due to incompetent closure of the mitral valve [1][2].

Breaking down the term:

  • "Mitral" = refers to the mitral valve (named because it resembles a bishop's mitre/hat)
  • "Regurgitation" = from Latin re- (back) + gurgitare (to flood) — literally "flooding back"

So the name tells you exactly what the problem is: blood floods backwards through the mitral valve.

"Leaking of blood back to LA" [1]

This is fundamentally a volume overload problem for the left heart — every beat, the LV ejects blood both forwards into the aorta AND backwards into the LA. The consequences depend entirely on whether this develops acutely or chronically.


  • MR is very common: 1 in 10 people > 75 years old has severe MR [1][2]
  • It is the most common valvular heart disease encountered in clinical practice in developed countries
  • In Hong Kong, the epidemiological profile is shifting:
    • Rheumatic heart disease (RHD) was historically the most common cause, and remains important in Hong Kong's older population and among immigrants from mainland China and Southeast Asia, though incidence is declining with improved living standards and antibiotic availability [2]
    • Degenerative causes (myxomatous degeneration, mitral valve prolapse, annular calcification) are now the leading aetiology in Hong Kong, mirroring Western trends, particularly as the population ages
    • Ischaemic (functional) MR is increasingly prevalent due to the high burden of coronary artery disease and hypertension in Hong Kong
  • Gender: Degenerative MR (MVP) has a slight female predominance; ischaemic MR is more common in males (reflecting CAD demographics)
  • Age: Degenerative MR increases with age; RHD-related MR typically presents in younger/middle-aged adults

High Yield — Epidemiology

MR is the most common significant valvular lesion in elderly populations. In Hong Kong, expect a mixed aetiology: degenerative disease dominates, but RHD is still tested and still relevant in the local context.


3. Anatomy and Function of the Mitral Valve Apparatus

Understanding MR requires understanding the mitral valve as a complex apparatus, not just two flaps of tissue. All valve disease relates to failure of one or more components of this apparatus [1].

The mitral valve apparatus has five interdependent components:

ComponentStructureFunction
Mitral annulusFibrous ring at the atrioventricular junctionProvides structural framework; contracts during systole to reduce orifice area and aid coaptation
Anterior leaflet (A1, A2, A3)Larger, semicircular; attached to ~1/3 of annular circumferenceCovers ~2/3 of the valve orifice; continuous with the aortic valve (aortomitral curtain)
Posterior leaflet (P1, P2, P3)Smaller, crescent-shaped; attached to ~2/3 of annular circumferenceCovers ~1/3 of the orifice; has 3 scallops (P2 is the largest and most commonly prolapsing segment)
Chordae tendineaeFibrous cords from papillary muscles to leaflet edges and bodiesTether the leaflets during systole to prevent prolapse into the LA
Papillary musclesTwo muscles arising from the LV free wall: anterolateral and posteromedialContract during systole to maintain chordal tension; the posteromedial papillary muscle has a single blood supply (from the PDA, usually RCA) making it more vulnerable to ischaemia

Additionally, the LV myocardium itself is considered a "sixth component" — LV geometry and contraction directly influence annular size and papillary muscle positioning.

During systole, LV pressure rises above LA pressure. The mitral leaflets are pushed upward toward the closed position by the pressure gradient, while the papillary muscles contract simultaneously to pull the chordae taut and prevent the leaflets from prolapsing (everting) into the LA. The net result is tight coaptation (apposition) of the anterior and posterior leaflets along a "coaptation zone" — this seal prevents regurgitation.

During diastole, the mitral valve opens to allow LA blood to fill the LV. The normal mitral valve area is 4–6 cm².

Key Concept — Why the Papillary Muscles Matter

The papillary muscles do NOT pull the valve shut. They prevent the valve from being blown open (prolapsing) by the high systolic LV pressure. Think of them as anchors — if an anchor breaks or moves, the sail (leaflet) flips the wrong way.

The posteromedial papillary muscle receives its blood supply from a single artery (usually the posterior descending artery from the RCA), whereas the anterolateral papillary muscle has dual supply (from both the LAD and LCx). This makes the posteromedial muscle highly susceptible to ischaemia/infarction — especially in inferior MI — and is the reason why ischaemic MR disproportionately involves this muscle [2].


4. Aetiology

MR can be classified aetiologically as primary (organic) vs. secondary (functional) — this distinction is critical because it determines management [1][2].

The valve leaflets or chordae themselves are structurally abnormal. The valve is the problem.

CauseMechanismNotes
Rheumatic heart diseasePost-streptococcal autoimmune valvulitis → fibrosis, retraction, and thickening of leaflets and chordae → poor coaptationCommonest cause overall (especially in Hong Kong/Asia); 50% associated with MS [2][3]. Typically affects young-to-middle-aged adults.
Mitral valve prolapse (MVP) / Myxomatous degenerationReplacement of normal dense collagen/elastin matrix of valvular fibrosa by loose myxomatous connective tissue → leaflet enlargement, redundancy, prolapse beyond annular planeMost common cause in Western countries; affects 2–3% of population. More common in females. Can be familial (AD with variable penetrance) or associated with connective tissue disorders (Marfan syndrome, Ehlers-Danlos syndrome) [2][4]
Infective endocarditis (IE)Vegetations destroy leaflet tissue; can cause leaflet perforation or chordal ruptureCan cause acute severe MR. Valve involvement: MV >> AV > TV > PV [3]
Connective tissue disordersMarfan syndrome, Ehlers-Danlos syndrome, osteogenesis imperfecta → weakened valve/chordal tissue → prolapse or chordal ruptureThink of these in young patients with MR + body habitus findings
Ruptured chordae tendineaeDegenerative, collagen disease, infective (IE), acute rheumatic heart disease → sudden loss of leaflet support → flail leaflet → acute severe MRCauses acute MR — a surgical emergency [2]
SLE (Libman-Sacks endocarditis)Non-infective verrucous vegetations on valve leaflets (both atrial and ventricular surfaces)Chronic, usually mild MR
Radiation valvulopathyFibrosis of valve leaflets and annulus post-radiotherapySeen in Hodgkin lymphoma survivors
CongenitalCleft mitral valve (especially in AV canal defects), parachute mitral valveRare; present in infancy/childhood

The valve leaflets are structurally normal, but the valve doesn't close properly because the supporting apparatus has been distorted by LV or LA disease. The ventricle (or atrium) is the problem.

This is described as a "casing problem" of the mitral valve [1].

CauseMechanismNotes
Ischaemic heart disease / MIPapillary muscle displacement (due to LV remodelling after MI) → restricted leaflet closure + annular dilation → functional MR [1][2]Especially inferior MI (posteromedial papillary muscle). This is NOT the same as papillary muscle rupture (which causes acute MR).
Dilated cardiomyopathy (DCMP) / LV dilation from any causeAnnular dilation + displacement of papillary muscles laterally → leaflets tethered and cannot coaptCAD, DCMP [2]
HOCM with SAMAsymmetric septal hypertrophy → anterior displacement of papillary muscles → systolic anterior motion (SAM) of the mitral valve anterior leaflet toward the septum → MR + LVOT obstructionThe MR jet is directed posteriorly. Severity directly proportional to LV outflow obstruction [4]
Atrial functional MRChronic AF → severe LA dilation → annular dilation (even without LV disease) → MRIncreasingly recognized entity

Lecture Slide Key Point

The lecture slide specifically contrasts a normal mitral valve with functional mitral regurgitation, showing papillary muscle displacement, restricted leaflet closure, chordal tethering, and annular dilation — all secondary to LV remodelling [1]. Students frequently confuse functional MR with structural valve disease. In functional MR, the valve is normal — it's the ventricle that's sick.


5. Pathophysiology

This is where MR gets interesting — and where exam questions love to test. The haemodynamic consequences differ dramatically between acute and chronic MR.

In MR, during systole, the LV ejects blood through two exits:

  1. Forward through the aortic valve into the aorta (effective stroke volume)
  2. Backward through the incompetent mitral valve into the LA (regurgitant volume)

The regurgitant fraction = regurgitant volume / total stroke volume.

This means:

  • Forward cardiac output is reduced (→ fatigue, weakness)
  • LA receives an abnormal volume load (→ raised LA pressure → pulmonary congestion)
  • LV receives increased volume in diastole (regurgitant blood returns from LA → volume overload)

Chronic MR develops gradually — the heart has time to compensate.

Phase 1 — Compensation (may last ≥ 10 years):

  • Gradual LA dilation with ↑pressure only during systole → the large, compliant LA acts as a "buffer," absorbing regurgitant volume without much rise in mean LA pressure
  • Usually little or no symptoms early on for ≥ 10 years (cf. MS, which is symptomatic much earlier)
  • The LV also dilates (eccentric hypertrophy) to accommodate the increased total stroke volume
  • ↑LA compliance results in exaggerated regurgitant fraction — paradoxically, as the LA becomes more compliant, it "invites" more regurgitant flow (because the impedance to backward flow decreases)
  • Early symptoms dominated by low forward cardiac output: fatigue, weakness [2]
  • Pulmonary hypertension only occurs late when the LV fails due to volume overload [2]

Phase 2 — Decompensation:

  • Once severe, MR is NOT benign [2]
  • Patients develop symptoms at 10%/year, AF in 1/3 [2]
  • 90% of asymptomatic patients with normal LVEF will need surgery at 10 years [2]
  • The LV gradually fails from chronic volume overload → LV systolic dysfunction (↓LVEF)
  • Rising LA pressure → pulmonary venous hypertension → pulmonary arterial hypertension → RV failure

Key concept — LVEF is deceptively normal in MR: In MR, the LV ejects into two low-pressure chambers (aorta AND LA). The LA is a very low-impedance circuit. This means the LV can maintain a "normal" LVEF even when intrinsic myocardial contractility has already declined significantly. By the time LVEF drops below 60% in MR, the ventricle is already significantly impaired. This is why the surgical threshold for LVEF in MR is ≥ 60% (not 50% as in other conditions) — once it drops below 60%, irreversible LV damage may have occurred [2].

Critical Exam Concept

LVEF ≥ 60% is considered "normal" in the context of MR. If LVEF drops to 55% in a patient with severe MR, that's NOT reassuring — it indicates significant LV dysfunction and is an indication for surgery. Don't be fooled by a "normal" EF of 55% in MR!

Acute MR is a completely different beast — and a medical/surgical emergency.

Causes: chordal rupture, papillary muscle rupture (post-MI), leaflet perforation (IE), acute rheumatic fever, prosthetic valve dehiscence.

  • Rapid ↑LA pressure (no time to dilate) — the LA is small and non-compliant
  • Acute severe pulmonary hypertension with acute pulmonary oedema and intense distress [2]
  • The sudden volume overload is transmitted directly backward to the pulmonary veins → flash pulmonary oedema
  • Forward cardiac output drops precipitously → cardiogenic shock
  • The murmur in acute MR may be shorter and softer than in chronic MR (because the LV-LA pressure gradient equilibrates rapidly in late systole — the murmur may have a decrescendo quality [2])
  • This is a surgical emergency — medical therapy is a temporizing bridge

The lecture slides specifically illustrate this mechanism:

In ischaemic heart disease, the "casing problem" of the mitral valve involves: [1]

  1. Papillary muscle displacement — LV remodelling (post-MI dilation/scar) displaces the papillary muscles posterolaterally
  2. Restricted leaflet closure — the displaced papillary muscles pull the chordae taut, tethering the leaflets and preventing them from coapting at the annular plane
  3. Annular dilation — LV dilation stretches the mitral annulus, further widening the gap between leaflets

The result is a valve that is structurally normal but functionally incompetent — the leaflets simply cannot reach each other.


6. Classification

MR can be classified by several schemas:

6.1 By Aetiology: Primary vs. Secondary (as above)

6.2 By Acuity: Acute vs. Chronic (as above)

This classification describes leaflet motion relative to the annular plane and is the standard framework used by cardiac surgeons:

TypeLeaflet MotionMechanismExample
Type INormal leaflet motionAnnular dilation or leaflet perforationFunctional MR from DCMP (annular dilation); IE with leaflet perforation
Type IIExcessive leaflet motion (prolapse/flail)Chordal elongation or rupture → leaflet prolapses above annular planeMVP, chordal rupture (degenerative, IE)
Type IIIaRestricted leaflet motion in diastole (and systole)Leaflet/chordal thickening and retractionRheumatic heart disease
Type IIIbRestricted leaflet motion in systole onlyPapillary muscle displacement, chordal tetheringIschaemic/functional MR [1] — the leaflets open normally in diastole but are tethered and cannot close in systole

Carpentier Classification — Exam Favourite

Type IIIb is the classic "casing problem" shown in the lecture slides [1]. The leaflets are normal, but the remodelled LV pulls them apart during systole. This is distinguished from Type IIIa (rheumatic), where the leaflets themselves are stiff and restricted in BOTH systole and diastole.

ParameterMildModerateSevere
Regurgitant volume (mL/beat)< 3030–59≥ 60
Regurgitant fraction (%)< 3030–49≥ 50
Effective regurgitant orifice area (EROA, cm²)< 0.200.20–0.39≥ 0.40
Vena contracta (cm)< 0.30.3–0.69≥ 0.7
Colour-flow Doppler jet areaSmall, centralIntermediateLarge, reaching posterior LA wall

7. Clinical Features

7.1 Symptoms

The key teaching point: chronic MR is asymptomatic for years (≥ 10 years) [2]. When symptoms do appear, they progress through a predictable sequence based on the underlying haemodynamics:

SymptomPathophysiological Basis
Fatigue and weakness (early)Low forward cardiac output [2] — regurgitant blood goes backward into LA rather than forward to tissues. Total LV stroke volume is maintained but effective (forward) stroke volume is reduced.
Exertional dyspnoea (later)Occurs late when LV failure ensues [2]. Rising LA pressure (from LV decompensation and/or progressive MR) → transmitted backward to pulmonary veins → pulmonary venous congestion → interstitial/alveolar oedema → ↑work of breathing. Exercise worsens this because ↑HR shortens diastole (reducing forward flow) while ↑contractility may worsen MR.
Orthopnoea and PND (late)Supine position → redistribution of blood from lower extremities to central circulation → ↑preload → ↑LA pressure → pulmonary oedema. PND occurs because fluid reabsorption from interstitium occurs during sleep.
PalpitationsAF (from LA dilation) or ventricular ectopics (from LV remodelling). AF occurs in 1/3 of patients with chronic severe MR [2].
Peripheral oedema (very late)Right heart failure from chronic pulmonary hypertension — hydrostatic back-pressure in systemic veins → transudation into tissues.
Haemoptysis (rare)Rupture of bronchial veins secondary to pulmonary venous hypertension.

SymptomPathophysiological Basis
Acute pulmonary oedema — VERY hard to tolerate [2]Rapid ↑LA pressure (no time to dilate) → immediate transmission to pulmonary veins → flash pulmonary oedema. The non-compliant LA cannot buffer the regurgitant volume.
Acute severe dyspnoea at restSame mechanism — alveolar flooding impairs gas exchange
Cardiogenic shock (hypotension, tachycardia, oliguria, cold peripheries)Massive drop in effective forward cardiac output — regurgitant fraction may exceed 50–70%

Acute vs. Chronic MR — A Clinical Trap

Acute MR presents with flash pulmonary oedema and shock, often with a soft or inaudible murmur (because the LV-LA pressure gradient equilibrates quickly). Students who expect a loud murmur may miss the diagnosis. If a patient post-MI suddenly deteriorates with acute pulmonary oedema — think acute MR from papillary muscle dysfunction or rupture, even if you can't hear a loud murmur.

SignPathophysiological Basis
General inspection
Ankle oedemaIf RVF [2] — pulmonary hypertension → RV pressure overload → RV failure → systemic venous congestion → peripheral oedema
Malar flushCharacteristic of mitral valve disease (especially MS, but can occur in MR with pulmonary HTN) — ↓CO → reflex peripheral vasoconstriction with cutaneous venule dilation in cheeks
Pulse
Often regular ± small volume [2]Small volume reflects ↓effective forward stroke volume. Regular because AF is typically only seen if associated with MS or severe MR [2].
AF (if present)LA dilation → electrical remodelling + fibrosis → triggers and substrates for AF
Blood pressure
Normal or slightly low systolic BP↓forward stroke volume
JVP
Elevated JVPIf right heart failure has developed (late); prominent cv waves if secondary TR develops
Precordial palpation
Displaced thrusting apexLV dilation (eccentric hypertrophy from volume overload) [2] — the apex is displaced inferolaterally. "Thrusting" = hyperdynamic quality because the LV contracts vigorously to compensate for the regurgitant leak. Contrast with the "heaving" apex of AS/HTN (pressure overload, concentric hypertrophy).
± Systolic thrillTurbulent flow through the regurgitant orifice palpable at the apex [2] — indicates significant MR
± Parasternal heaveIf severe pulmonary hypertension [2] — RV hypertrophy from chronic ↑pulmonary pressures
Auscultation
Soft S1The incompetent mitral valve cannot close properly → ↓intensity of mitral component of S1. In normal physiology, S1 is generated by the abrupt tensing of closed mitral and tricuspid valves. If the mitral valve is leaky, it doesn't snap shut with the same tension. [2]
S2 heard but often obscured by murmurThe pansystolic murmur extends through S2, making it difficult to hear [2]
S3 usualAn S3 indicates rapid ventricular filling in early diastole. In MR, the LA is volume-loaded; when the mitral valve opens in diastole, the large volume of blood (accumulated regurgitant volume + normal pulmonary venous return) rushes into the LV, causing sudden deceleration of blood and vibration of the ventricular wall → S3. This is an important sign of haemodynamically significant MR. [2]
S4 if acute MRAn S4 indicates a stiff, non-compliant LV. In acute MR, the LV has not had time to dilate/remodel → it is relatively stiff → atrial contraction into a stiff LV generates S4. (In chronic MR, the LV is dilated and compliant, so S4 is absent.) [2]
Pansystolic murmur (PSM) best heard at apex radiating to axillaThis is the hallmark sign. MR produces a regurgitant jet throughout systole (from the moment LV pressure exceeds LA pressure — which is almost immediately after S1 — until the end of systole). The murmur radiates to the axilla because the regurgitant jet is typically directed posterolaterally (especially with anterior leaflet pathology). [2]
In ischaemic papillary muscle dysfunction, the regurgitant jet may be directed to the anterior LA → best heard at LSB/aortic areas (mimics ESM of AS) [2]In posterior leaflet restriction (ischaemic MR), the jet is directed anteriorly toward the aortic root and interatrial septum. This anterior jet direction means the murmur is heard at unusual locations — the LSB or even the aortic area — potentially leading to misdiagnosis as aortic stenosis.
May have decrescendo quality in acute MRDue to rapid equilibration of pressure [2] — in acute MR, the small non-compliant LA pressure rises rapidly during systole to approach LV pressure. As the pressure gradient narrows, flow velocity drops and the murmur fades → decrescendo rather than the classic pansystolic pattern.
Loud P2If pulmonary hypertension is present — ↑pulmonary artery pressure → forceful closure of the pulmonary valve → loud P2

ManoeuvreEffect on MR MurmurMechanism
Squatting↑Louder↑Preload (↑venous return) + ↑afterload (↑SVR) → ↑LV volume → ↑regurgitant flow
Valsalva (strain phase)↓Softer↓Preload → ↓LV volume → ↓regurgitant flow
Standing suddenly↓Softer↓Preload → same as above
Hand grip (isometric exercise)↑Louder↑Afterload → ↑resistance to forward flow → more blood goes backward through MV
Amyl nitrite↓Softer↓Afterload → ↑forward flow → ↓regurgitant flow

Exception — MVP murmur: In MVP, manoeuvres that ↓LV volume (Valsalva, standing) cause the click to come earlier and the murmur to become longer and louder — because a smaller LV means the prolapse occurs earlier in systole.

Murmur Radiation — Location Tells You Aetiology

  • Posterior leaflet pathology (e.g., P2 prolapse) → jet directed anteriorly → murmur radiates toward the sternum/aortic area
  • Anterior leaflet pathology (e.g., A2 prolapse) → jet directed posteriorly → murmur radiates to the axilla and back
  • Ischaemic MR (posterior papillary muscle dysfunction) → posterior leaflet restricted → anterior jet → heard at LSB/aortic area, mimics AS [2]

8. Mitral Valve Prolapse (MVP) — Special Consideration [2][4]

Since MVP is the most common cause of primary MR in developed countries and is commonly tested, it warrants separate attention.

  • Definition: Displacement of one or both mitral leaflets ≥ 2 mm above the mitral annular plane during systole
  • Occurs in 2–3% of the population [4]
  • More common in young women (for non-syndromic MVP)

  • Degenerative: myxomatous degeneration — enlargement of leaflet with replacement of normal dense collagen and elastin matrix of valvular fibrosa by loose myxomatous connective tissue [4]
  • Congenital: primary AD inheritance with variable penetrance or associated with connective tissue disorders (Marfan syndrome), secundum ASD, Turner syndrome, PDA, WPWS, polycystic kidney disease, DCMP/HCMP [4]

  • Asymptomatic (most patients)
  • Arrhythmia: palpitation, atypical chest pain ('systolic click-murmur syndrome')
    • Mechanism: mitral valve prolapse → excessive stress on papillary muscle → ischaemia and chest pain [4]
  • Symptoms of MR: presents acutely (due to chordal rupture) or chronically (due to progressive MR) [4]

  • Mid-systolic click followed by late systolic crescendo murmur loudest at the LLSB / apex
  • The click is generated by sudden tensing of the redundant leaflet and chordae as they reach maximum prolapse
  • Murmur: late systolic, crescendo — not pansystolic (unless MR is severe)

  • Embolic stroke (rare — platelet-fibrin deposits on redundant leaflet)
  • Endocarditis (abnormal valve surface predisposes to bacterial seeding)
  • Arrhythmia (prolonged QT)
  • Progression to severe MR (chordal rupture, progressive myxomatous degeneration)

FeatureAcute MRChronic MRMS
LA sizeSmall (normal)Large (dilated)Large (dilated)
LA pressureVery highNormal-to-mildly elevated (until decompensation)Chronically elevated
LV sizeNormalDilated (eccentric hypertrophy)Small (underfilled)
Pulmonary HTNSevere, acuteLate onsetEarly and progressive
Main symptomAcute pulmonary oedemaFatigue → dyspnoeaDyspnoea early
MurmurShort, decrescendo, may be softPansystolic, loudMid-diastolic rumble
AFUncommonLate (1/3)Early (45%)


High Yield Summary

Definition: Backward leak of blood from LV → LA during systole due to mitral valve incompetence.

Epidemiology: Most common valvular disease; 1 in 10 people > 75 years old has severe MR [1].

Aetiology:

  • Primary (organic): RHD (commonest in HK/Asia, 50% a/w MS), MVP/myxomatous degeneration, IE, chordal rupture, CT disorders
  • Secondary (functional): Ischaemic (papillary muscle displacement + annular dilation), DCMP, HOCM with SAM

Pathophysiology:

  • Chronic: LA dilates → compensated for years → late LV failure → pulmonary HTN → RV failure
  • Acute: LA cannot dilate → flash pulmonary oedema + cardiogenic shock
  • LVEF ≥ 60% is the threshold for "normal" in MR (the LA acts as a low-impedance pop-off valve)

Clinical Features:

  • Symptoms: fatigue/weakness (early) → exertional dyspnoea (late) → orthopnoea/PND → peripheral oedema
  • Signs: displaced thrusting apex, soft S1, S3, PSM at apex → axilla
  • Acute MR: decrescendo murmur, S4, flash pulmonary oedema
  • Ischaemic MR jet may be anterior → heard at LSB, mimicking AS

Carpentier Classification: Type I (normal motion, annular/perforation), Type II (excessive motion, prolapse), Type IIIa (restricted systole + diastole, rheumatic), Type IIIb (restricted systole only, ischaemic)


Active Recall - Mitral Regurgitation (Definition to Clinical Features)


[1] Lecture slides: Cardiac Surgery Tutorial_Prof. D Chan.pdf (p38, p39, p43) [2] Senior notes: Ryan Ho Cardiology.pdf (p155, p157, p160) [3] Senior notes: Maksim Medicine Notes.pdf (p35, p37, p39) [4] Senior notes: Ryan Ho Cardiology.pdf (p157 — MVP section; p167 — HOCM with SAM)

Differential Diagnosis of Mitral Regurgitation

When you encounter a patient with suspected MR — say, a pansystolic murmur at the apex — the clinical challenge is twofold: (1) confirming that the murmur truly represents MR rather than another condition that mimics it, and (2) determining the underlying aetiology of the MR itself. Let's work through both systematically.

The differential diagnosis of MR operates on two levels:

  1. Mimics of MR — other conditions that produce a pansystolic or systolic murmur that can be confused with MR
  2. Aetiological differentiation — once MR is confirmed, determining why the valve is leaking (primary vs. secondary, acute vs. chronic)

Level 1: Conditions That Mimic MR (Differential of the Pansystolic/Systolic Murmur)

The cardinal sign of MR is a pansystolic murmur (PSM) best heard at the apex, radiating to the axilla [2]. But several other conditions can produce systolic murmurs that may be confused with MR. The key to differentiation lies in understanding where each murmur is best heard, why it has its particular character, and how dynamic manoeuvres and bedside examination separate them.

FeatureMRTR
Best heardApexLeft lower sternal border (LLSB)
RadiationAxillaRight sternal border; may radiate to subxiphoid
InspirationNo significant change (or slight ↓)↑ with inspiration (Carvallo's sign) [3]
ApexDisplaced, thrustingUsually not displaced (unless biventricular failure)
Associated signsLV failure signsRV failure signs: ↑JVP with prominent cv waves, pulsatile hepatomegaly, peripheral oedema, ascites

Why does TR get louder with inspiration? Inspiration increases venous return to the right heart (↓intrathoracic pressure → ↑pressure gradient from systemic veins to RA). This ↑RV preload → ↑RV volume → ↑regurgitant flow across the tricuspid valve → louder murmur. This is Carvallo's sign — the single most useful bedside manoeuvre to distinguish TR from MR [3].

Why does MR NOT increase with inspiration? The left heart is "downstream" of the pulmonary circulation. While inspiration transiently pools blood in the pulmonary vasculature (↓LV preload slightly), the effect on MR murmur intensity is minimal or slightly decreasing — the opposite of TR.

Carvallo's Sign

Carvallo's sign: TR = pansystolic murmur louder in inspiration [3]. This is the single most tested bedside manoeuvre for distinguishing TR from MR. The mechanism is simple: inspiration ↑venous return to the right heart → ↑RV volume → ↑regurgitant flow.

FeatureMRAS
Murmur typePansystolic (constant intensity throughout systole)Ejection systolic (crescendo-decrescendo)
Best heardApexRight upper sternal border (aortic area)
RadiationAxillaCarotids
PulseSmall volume (if severe) but normal characterLow-volume, slow-rising pulse [3]
S2Soft S1; S2 obscured by murmurSoft/absent A2, reverse splitting of S2 [3]
ApexDisplaced, thrusting (volume overload)Heaving apex (pressure overload, concentric LVH) [3]
Extra soundsS3S4 [3]

The Gallavardin phenomenon — a common trap: AS can present as an ejection systolic murmur (ESM) best heard at the apex, mimicking MR. This is the Gallavardin phenomenon, more common in the elderly [3]. Why does this happen? In calcific AS, the murmur has two components — a low-frequency component transmitted to the apex (sounding like MR) and a high-frequency component transmitted to the carotids. The carotid radiation and slow-rising pulse help distinguish it.

The reverse trap — ischaemic MR mimicking AS: In ischaemic papillary muscle dysfunction, the regurgitant jet may be directed to the anterior LA → best heard at LSB/aortic areas (mimicking ESM of AS) [2]. Here, the posterior leaflet is tethered by the displaced papillary muscle, directing the jet anteriorly. The key differentiator is the pulse character (normal or small volume in MR vs. slow-rising in AS) and echocardiography.

FeatureMRHOCM
MurmurPSM at apex → axillaESM at LLSB [4]; may also have a separate MR murmur
ApexDisplaced, thrustingNon-displaced [4] (LV cavity is small due to hypertrophy)
Valsalva↓Softer↑Louder (↓preload → ↓LV cavity size → ↑obstruction)
Squatting↑Louder↓Softer (↑preload + ↑afterload → ↑LV cavity size → ↓obstruction)
PulseSmall volumeJerky pulse (dynamic obstruction causes rapid early upstroke then mid-systolic dip)

Why does HOCM cause MR? Asymmetric septal hypertrophy (ASH) → anterior displacement of papillary muscles → systolic anterior motion (SAM) of the mitral valve anterior leaflet toward the septum → MR. The severity of MR is directly proportional to the LV outflow obstruction [5]. So in HOCM, MR and LVOT obstruction are linked — anything that worsens obstruction worsens MR.

Critical distinction with dynamic manoeuvres: HOCM is the only common murmur that gets louder with Valsalva (strain phase). All other systolic murmurs generally get softer. This is because ↓preload in HOCM → ↓LV cavity size → the hypertrophied septum and anterior mitral leaflet are brought closer together → ↑obstruction → louder murmur.

Important d/dx for MVP

The senior notes specifically list the important differential diagnoses for MVP: other causes of MR (e.g., DCMP), TR, AS, HOCM (ESM at LLSB, non-displaced apex) [4]. These are the four conditions most commonly confused with MVP on auscultation.

FeatureMRVSD
MurmurPSM at apex → axillaPSM at LLSB → all over precordium
Best heardApexLLSB (3rd–4th intercostal space)
ThrillApexLLSB
RadiationAxillaAcross the precordium, NOT to axilla
Associated featuresLV dilation signsDepends on shunt size; large VSD → pulmonary HTN

Why is VSD a PSM? During systole, the LV pressure greatly exceeds RV pressure. Blood is shunted from LV → RV through the defect throughout systole, creating a continuous pressure gradient and therefore a pansystolic murmur. The mechanism is analogous to MR (constant systolic pressure gradient driving flow), but the flow goes from LV → RV rather than LV → LA, so the murmur is located at the LLSB (over the septum) rather than the apex.

Paradox of VSD murmur intensity: A small, restrictive VSD produces a louder murmur than a large, non-restrictive VSD. This is because in a small VSD, the pressure gradient is high → high-velocity turbulent flow → loud murmur. In a large VSD, pressures equalize between ventricles → low-velocity flow → soft murmur (or even absent in Eisenmenger syndrome when the shunt reverses).

ConditionKey Distinguishing Feature
Innocent/flow murmurSoft, ejection systolic, grade ≤ 2/6, no radiation, normal S1/S2, no associated symptoms. Common in children, pregnancy, high-output states (anaemia, thyrotoxicosis, fever). Disappears on standing/Valsalva.
Aortic regurgitation (functional murmur at apex)Austin-Flint murmur: mid-diastolic low-pitched apical murmur due to heavy AR regurgitation jet impinging on anterior leaflet of mitral valve → turbulent atrial outflow [6]. This is a diastolic murmur mimicking MS, NOT MR — but it can coexist with MR in mixed valve disease.
Mitral stenosis (MS)Mid-diastolic rumble at apex (not systolic). But MS and MR frequently coexist (RHD causes both; 50% of RHD-related MR is associated with MS [2]). An opening snap and presystolic accentuation (if in sinus rhythm) distinguish the MS component.
Pulmonary regurgitation (PR) / Graham-Steell murmurEarly diastolic murmur at the pulmonic area, associated with loud P2, indicating severe MS [3] — this is secondary to pulmonary hypertension from any cause (including severe MR). Not a mimic of MR per se, but a consequence.

Once MR is confirmed (by auscultation, echocardiography, or both), the next step is determining the underlying cause. This guides management — primary MR may benefit from valve repair/replacement, while secondary MR requires treatment of the underlying cardiac pathology.

Key Clinical Clues for Aetiological Differentiation

CluePoints Toward
Young patient, migratory joint history, subcutaneous nodulesRheumatic heart disease
Mid-systolic click + late systolic murmur in a young femaleMVP / Myxomatous degeneration
Tall, thin habitus, arachnodactyly, lens subluxation, pectus excavatumMarfan syndrome (connective tissue)
Fever, weight loss, new-onset regurgitation murmur, peripheral stigmata (Osler nodes, Janeway lesions, splinter haemorrhages, Roth spots) [7]Infective endocarditis
Acute onset post-MI (especially inferior MI), haemodynamic collapsePapillary muscle rupture/dysfunction (ischaemic)
Known DCMP / progressive LV dilation on prior imagingFunctional MR from annular dilation
ESM at LLSB, non-displaced apex, jerky pulse, FHx of sudden deathHOCM with SAM [4][5]
Prosthetic valve, prior valve repair, positive blood culturesProsthetic valve endocarditis or dehiscence [7]
Chronic AF with progressive LA dilation, no LV dysfunctionAtrial functional MR
History of chest radiation (e.g., Hodgkin lymphoma)Radiation valvulopathy
Malar rash, arthralgia, serositis, ANA positivitySLE (Libman-Sacks endocarditis)

Level 3: Differential of the Clinical Presentation of MR

Patients with MR don't present saying "I have mitral regurgitation." They present with symptoms — dyspnoea, fatigue, or acute pulmonary oedema — that have a broad differential diagnosis. The clinician must consider the full differential of these presentations.

CategoryConditionDistinguishing Feature
CardiacOther valvular disease (AS, MS, AR)Different murmur characteristics; echo is definitive
Heart failure (HFrEF/HFpEF)MR itself is a common cause of LV volume overload leading to HF [8]. Other causes: CAD, DCMP, HTN. Echo differentiates.
Constrictive pericarditisKussmaul's sign, pericardial knock, calcification on CXR/CT
PulmonaryCOPD, asthmaWheeze, hyperinflation on CXR, obstructive pattern on spirometry
Interstitial lung diseaseBibasal fine crackles, restrictive pattern, HRCT findings
Pulmonary hypertension (primary)Loud P2, RV heave, no LV signs
SystemicAnaemiaPallor, flow murmur (ESM), high-output state
ThyrotoxicosisWeight loss, tremor, tachycardia, AF, thyroid function tests
DeconditioningObesity, sedentary lifestyleDiagnosis of exclusion

CauseKey Feature
Acute MR (chordal/papillary muscle rupture)Post-MI, IE, sudden haemodynamic collapse, soft/decrescendo murmur
Acute MI / ACSChest pain, ECG changes, troponin elevation
Acute aortic regurgitationAortic dissection, IE — tearing chest pain, asymmetric BP, early diastolic murmur [3]
Hypertensive crisis (flash pulmonary oedema)Severe hypertension, often with renal artery stenosis
Acute decompensated HFKnown HF history, precipitant (medication non-compliance, infection, arrhythmia)
Acute VSD (post-MI)New harsh PSM at LLSB post-MI, thrill

Post-MI Mechanical Complications — DDx of Acute Deterioration

After MI, sudden haemodynamic deterioration with a new murmur must prompt urgent differentiation between: (1) acute MR from papillary muscle rupture/dysfunction — PSM at apex; (2) acute VSD — PSM at LLSB with thrill; (3) free wall rupture — cardiac tamponade, PEA. All are surgical emergencies. A bedside echo (or urgently a TEE) is the fastest way to differentiate. Do NOT wait for catheterisation.


The following systematic approach can be used at the bedside to narrow the differential when a systolic murmur is heard:

StepAssessmentWhat It Tells You
1. LocationWhere is it loudest?Apex = MR or MVP; LLSB = TR, HOCM, or VSD; RUSB = AS
2. RadiationWhere does it go?Axilla = MR; carotids = AS; across precordium = VSD
3. CharacterPSM or ESM?PSM = MR, TR, VSD; ESM = AS, HOCM, innocent
4. InspirationLouder?Yes = right-sided (TR) — Carvallo's sign
5. ValsalvaLouder?Yes = HOCM only; softer = everything else
6. PulseCharacter?Slow-rising = AS; jerky = HOCM; collapsing = AR
7. ApexPosition and character?Displaced thrusting = MR (volume overload); heaving = AS/HTN; non-displaced = HOCM
8. Extra soundsClicks, S3, S4?Mid-systolic click = MVP; S3 = chronic MR; S4 = AS or acute MR

Not all PSMs are from valve disease. Always consider:

  • Prosthetic heart valve dysfunction: mechanical valve — listen for abnormal clicks or new murmurs; bioprosthetic valve — degeneration over time
  • Microangiopathic haemolytic anaemia (MAHA) from prosthetic valve: prosthetic heart valve can cause intravascular RBC fragmentation (non-immune haemolysis) [9] — presents with anaemia, jaundice, and schistocytes on blood film. The MR here is from paravalvular leak or valve dysfunction.
  • Non-bacterial thrombotic endocarditis (NBTE): deposition of sterile thrombus on valve leaflets in the context of metastatic malignancy (marantic endocarditis, especially mucin-producing adenocarcinoma), thrombophilia, or SLE (Libman-Sacks endocarditis) [7]. Site: mitral valve > aortic valve > tricuspid valve > pulmonary valve [7]. This can cause MR but does not respond to antibiotics — treatment is directed at the underlying cause.

High Yield Summary — Differential Diagnosis of MR

Mimics of MR murmur:

  • TR: PSM at LLSB, ↑with inspiration (Carvallo's sign), RV failure signs
  • AS: ESM at RUSB → carotids, slow-rising pulse, heaving apex; Gallavardin phenomenon can mimic MR at apex
  • HOCM: ESM at LLSB, non-displaced apex, jerky pulse, ↑with Valsalva, associated SAM causing MR
  • VSD: PSM at LLSB, thrill at LLSB, does NOT radiate to axilla

Ischaemic MR can mimic AS — anterior jet direction from posterior leaflet tethering → heard at LSB/aortic area.

Aetiological DDx: Primary (RHD, MVP, IE, CT disorders) vs. Secondary (ischaemic, DCMP, HOCM with SAM)

Post-MI new murmur: Must differentiate acute MR (papillary muscle rupture) from acute VSD and free wall rupture — all surgical emergencies. Bedside echo is key.


Active Recall - Differential Diagnosis of Mitral Regurgitation

References

[2] Senior notes: Ryan Ho Cardiology.pdf (p155, p157) [3] Senior notes: Maksim Medicine Notes.pdf (p35, p37) [4] Senior notes: Ryan Ho Cardiology.pdf (p157 — MVP section, footnote 150 — important d/dx) [5] Senior notes: Ryan Ho Cardiology.pdf (p167 — HOCM with SAM) [6] Senior notes: Ryan Ho Fundamentals.pdf (p36 — Austin-Flint murmur, diastolic murmurs) [7] Senior notes: Ryan Ho Cardiology.pdf (p148–149 — infective endocarditis, NBTE) [8] Senior notes: Maksim Medicine Notes.pdf (p18 — heart failure, aetiology) [9] Senior notes: Ryan Ho Haemtology.pdf (p137 — MAHA from prosthetic heart valve)

Diagnostic Criteria, Algorithm, and Investigations for Mitral Regurgitation

Unlike conditions such as infective endocarditis (which has formal diagnostic criteria like the Modified Duke Criteria), MR does not have a single codified set of "diagnostic criteria." Instead, the diagnosis of MR involves three sequential questions:

  1. Is MR present? (Clinical suspicion → confirmation by echocardiography)
  2. How severe is it? (Grading by echocardiographic parameters)
  3. What is causing it? (Aetiology — primary vs. secondary; acute vs. chronic)

The answers to all three questions determine management. Let's work through each systematically.


MR should be suspected clinically whenever you encounter:

  • A pansystolic murmur (PSM) best heard at the apex, radiating to the axilla [2]
  • A mid-systolic click followed by a late systolic murmur (suggests MVP as the underlying cause) [4]
  • Unexplained heart failure symptoms (especially in a patient with known risk factors for MR — prior MI, RHD, connective tissue disease, DCMP)
  • Acute pulmonary oedema in the context of MI or IE (think acute MR) [2]
  • An incidental finding on echocardiography performed for another indication

Key Clinical Principle

The clinical diagnosis of MR is made at the bedside by auscultation, but the definitive diagnosis, severity grading, and aetiological assessment all require echocardiography. You cannot grade MR severity by murmur intensity alone — a loud murmur does not always mean severe MR (and in acute MR, the murmur may be soft or decrescendo).


2. Severity Grading of MR — Echocardiographic Criteria

MR grading is based on qualitative and quantitative parameters [1].

This is the closest thing to formal "diagnostic criteria" for MR — the echocardiographic severity classification. The 2020/2021 ACC/AHA and 2021 ESC guidelines both use a multi-parametric integrative approach, combining qualitative, semi-quantitative, and quantitative Doppler parameters.

Effective regurgitant orifice area (EROA) is the most recommended tool in MR severity assessment [1].

ParameterMildModerateSevere
EROA (mm²)< 2020–39≥ 40 [1]
Regurgitant volume (mL/beat)< 3030–59≥ 60 [1]
Regurgitant fraction (%)< 3030–49≥ 50

Why is EROA the best parameter?

EROA measures the cross-sectional area of the regurgitant orifice at its narrowest point (the "vena contracta"). It is flow-independent — meaning it reflects the actual anatomical size of the leak rather than being influenced by loading conditions (preload, afterload, heart rate). It is calculated using the PISA method (Proximal Isovelocity Surface Area):

  • The regurgitant blood accelerates as it approaches the narrow regurgitant orifice, forming concentric hemispheric shells of equal velocity (like water approaching a drain)
  • On colour Doppler, the aliasing boundary (where colour changes from blue to red) represents a hemisphere of known velocity
  • The flow through this hemisphere equals the flow through the regurgitant orifice: EROA = 2πr² × aliasing velocity / peak MR velocity

Why different thresholds for primary vs. secondary MR?

The 2021 ESC guidelines use lower thresholds for severe secondary MR (EROA ≥ 20 mm², RVol ≥ 30 mL) compared to primary MR (EROA ≥ 40 mm², RVol ≥ 60 mL). This is because in secondary MR:

  • The LV is already dilated and dysfunctional — even a "moderate" amount of regurgitation has a disproportionately negative impact on an already failing ventricle
  • The regurgitant orifice in secondary MR is often crescent-shaped (along the coaptation line) rather than circular, so the PISA method may underestimate the true EROA

ParameterMildModerateSevere
Vena contracta width (mm)< 33–6.9≥ 7
Colour-flow jet area / LA area (%)< 2020–39≥ 40
Pulmonary vein flowSystolic dominantSystolic bluntingSystolic flow reversal

Why does severe MR cause pulmonary vein systolic flow reversal? Normally, blood flows from the pulmonary veins into the LA during both systole and diastole (systolic dominant pattern). In severe MR, the regurgitant jet increases LA pressure so much during systole that it exceeds pulmonary venous pressure — blood is actually pushed backwards into the pulmonary veins. This is a highly specific sign of severe MR.

ParameterMildModerateSevere
MR jet appearanceSmall, thin, centralIntermediateLarge, eccentric, wall-hugging, or very wide central jet
Mitral valve morphologyNormal or mild changesModerate thickening/prolapseFlail leaflet, ruptured papillary muscle, severe prolapse
LV/LA sizeNormalNormal or mildly dilatedDilated (unless acute)

ParameterSignificance
LVEFIn primary MR, LVEF ≥ 60% is considered "normal" [2] — because the LV ejects into both the aorta and the low-impedance LA, artificially inflating EF. LVEF cutoff is higher for MR because MR is a volume loading condition → LVEF should be high [4]. LVEF < 60% in severe MR indicates significant LV dysfunction.
LV end-systolic diameter (LVESD)LVESD ≥ 40 mm indicates LV dilation beyond compensation and is a trigger for surgery even in asymptomatic patients [2]
LA volume index≥ 60 mL/m² supports chronicity and haemodynamic significance
Pulmonary artery systolic pressure (PASP)Estimated from TR jet velocity. PASP > 50 mmHg at rest indicates significant pulmonary hypertension — a trigger for intervention
Tricuspid annular plane systolic excursion (TAPSE)Assesses RV function. TAPSE < 17 mm indicates RV dysfunction secondary to pulmonary hypertension

Exam High Yield — EROA Threshold

EROA > 40 mm² and RVol > 60 mL indicate severe primary MR [1]. These are the most tested thresholds. For secondary MR, remember the lower thresholds: EROA ≥ 20 mm² and RVol ≥ 30 mL (ESC 2021). The reason for the difference is that a sick ventricle tolerates even "moderate" regurgitation poorly.


The following algorithm outlines the systematic approach from clinical suspicion to definitive management planning:

Why TTE first, then TEE?

  • Transthoracic echocardiography (TTE) is the first-line investigation — non-invasive, bedside, widely available, and sufficient to diagnose MR, grade severity, and assess LV function in most cases [2][10]
  • Transesophageal echocardiography (TEE) is reserved for specific situations [10]:
    • When TTE is non-diagnostic or image quality is poor (obesity, lung hyperinflation, chest wall deformity)
    • Prosthetic valve — TTE has acoustic shadowing from the prosthesis that obscures the LA and mitral valve [10]
    • When viewing posterior structures (mitral valve) — the oesophagus sits directly behind the LA, giving TEE a superior view of the mitral valve apparatus [10]
    • Pre-operative planning — TEE provides detailed assessment of valve anatomy, leaflet involvement (which scallops are affected), and feasibility of repair
    • Intraoperative — TEE is used during MV repair to assess the result immediately after coming off bypass
    • Suspected IE — TEE has higher sensitivity for vegetations (~95%) vs. TTE (~65%) [10]

4. Investigation Modalities — Detailed Findings and Interpretation

The ECG does not diagnose MR but provides important clues about chronicity, haemodynamic severity, and aetiology.

FindingInterpretationMechanism
Atrial fibrillation (AF) [2][3]Chronic LA dilation → electrical remodelling → AF. Present in ~1/3 of severe chronic MR. New-onset AF is a trigger for surgical intervention.LA dilation stretches atrial myocytes → altered refractoriness + fibrosis → re-entrant circuits
P mitrale [2][3]Bifid P wave (duration > 120 ms) in lead II, or prominent negative deflection in V1. Indicates LA enlargement/hypertrophy.LA takes longer to depolarise when enlarged → prolonged P wave with two peaks (right atrium then left atrium).
LVH [2][3]Increased QRS voltages meeting Sokolov-Lyon criteria: S wave depth in V1 + tallest R in V5-6 > 35 mm [2]. Indicates LV volume overload.Eccentric LV hypertrophy from chronic volume overload → ↑myocardial mass → ↑depolarisation voltage.
LV strain patternST depression + T-wave inversion in lateral leads (V5, V6, I, aVL)Subendocardial ischaemia from demand-supply mismatch in hypertrophied myocardium
Normal ECGDoes NOT exclude MR. Mild-to-moderate MR may have a completely normal ECG.No significant haemodynamic effect yet

MVP-specific ECG findings [4]:

  • Normal ± non-specific ST depression in inferior leads [4]
  • ST-T changes may reflect papillary muscle traction/ischaemia
  • Rarely: prolonged QT interval (associated arrhythmia risk)

The CXR provides indirect evidence of MR and its haemodynamic consequences:

FindingInterpretationMechanism
LA enlargement [2]Double density sign behind the heart, splaying of carina (> 90°), posterior displacement of oesophagus on lateral view, straightening of left heart borderChronic volume overload of LA from regurgitant flow
LV enlargement [2]Cardiothoracic ratio > 0.5 on PA view, apex displaced below diaphragm and posteriorly on lateralLV eccentric hypertrophy. Key differentiator from MS — in MS, the LV is normal or small (underfilled), while in MR the LV is enlarged. "LV enlargement — not in MS" [2]
Pulmonary congestion [2]ABCDE mnemonic [8]: Alveolar oedema (bat-wing opacities), Kerley B lines, Cardiomegaly, Dilated upper lobe vessels (cephalisation), pleural Effusion↑LA pressure → ↑pulmonary venous pressure → transudation into interstitium and alveoli
Mitral valve calcificationSeen on lateral CXR as calcification in the region of the mitral annulusSuggests rheumatic or degenerative aetiology
Normal CXRDoes NOT exclude MR. Chronic compensated MR may have a normal CXR.Compliant, dilated LA buffers pressure without significant pulmonary congestion

Acute MR on CXR: Fulminant pulmonary oedema with a normal-sized heart — this is a critical clue. The LA and LV have not had time to dilate, so the cardiac silhouette is normal despite severe pulmonary congestion. If you see acute pulmonary oedema with a normal heart size, think acute MR (or other acute valvular catastrophe/flash pulmonary oedema from renal artery stenosis/hypertensive emergency).

4.3 Echocardiography — The Definitive Investigation

Echocardiography is the single most important investigation in MR. It simultaneously:

  • Confirms the diagnosis
  • Grades severity
  • Determines the mechanism and aetiology
  • Assesses LV and RV function
  • Guides surgical planning

Standard Views for MR Assessment:

ViewWhat It Shows
Parasternal long axis (PLAX)LV and LA size, anterior and posterior mitral leaflets (A2/P2), MR jet direction, LVOT
Parasternal short axis (PSAX) at mitral valve level"Fish-mouth" view of the MV orifice, identifies which scallop is prolapsing/flailing
Apical 4-chamber (A4C)All four chambers, MR jet extent into LA, measurement of EROA by PISA, PASP from TR jet
Apical 2-chamber (A2C)LA, LV, anterior and inferior walls — complements A4C for biplane assessment

Key Echo Findings and Their Interpretation:

FindingSignificance
LV dilatation and function [2]Assess LV dilatation and function — LVEDD, LVESD, LVEF. Remember: LVEF < 60% in MR = LV dysfunction.
Severity of regurgitation [2]Colour Doppler jet area, vena contracta, PISA/EROA, RVol, regurgitant fraction, pulmonary vein flow pattern
Underlying valvular defects [2]Leaflet thickening (RHD), prolapse/flail (MVP/chordal rupture), vegetations (IE), restricted motion (ischaemic), SAM (HOCM), annular dilation
LA sizeLA volume index ≥ 60 mL/m² supports chronic significant MR
PASPEstimated from TR jet using modified Bernoulli equation: PASP = 4 × (TR jet velocity)² + RA pressure. PASP > 50 mmHg = significant pulmonary HTN

TEE provides superior resolution of the mitral valve apparatus because the oesophageal transducer is positioned directly behind the LA with no intervening lung or bone.

Indications for TEE in MR:

  • Prosthetic valve assessment — avoids acoustic shadowing [10]
  • When viewing posterior structures (mitral valve) [10]
  • TTE non-diagnostic or discordant with clinical findings
  • Pre-operative surgical planning (which scallops are involved, feasibility of repair)
  • Suspected IE with negative TTE
  • Intraoperative guidance during MV repair
  • Assessment for transcatheter edge-to-edge repair (TEER / MitraClip) candidacy
  • Posterior systolic displacement of MV into LA (diagnostic) [4] — one or both leaflets prolapse ≥ 2 mm above the annular plane during systole, best seen in PLAX view
  • Leaflet redundancy, thickening (> 5 mm suggests myxomatous degeneration)
  • ± flail segment if chordal rupture has occurred

TTE vs. TEE — When to Use Which

TTE first — always. It's non-invasive, available, and sufficient for most patients. TEE is reserved for: (1) prosthetic valves, (2) poor TTE windows, (3) suspected IE with negative TTE, (4) pre-operative planning, (5) intraoperative assessment. TEE is particularly useful for the mitral valve because the oesophagus is immediately posterior to the LA [10].

Cardiac catheterisation is not routinely done for MR diagnosis [2]. Its role has been largely supplanted by echocardiography. However, it still has specific indications:

IndicationPurpose
Assessment of concomitant CAD in preparation for MV surgery [2]Coronary angiography is performed pre-operatively to determine if CABG should be done at the same time as valve surgery. This is the primary indication for cardiac catheterisation in MR.
Assess severity of concomitant CAD and MR when surgical intervention is considered [4]Left ventriculography can quantify regurgitation grade (Sellers classification I–IV), but this is rarely the primary method of severity assessment now.
Discordance between clinical and echo findingsRight heart catheterisation can directly measure LA pressure (or PCWP as a surrogate), systolic v wave in LA or pulmonary artery wedge pressure [2], confirming haemodynamic significance. A tall v wave on the PCWP tracing is characteristic of severe MR — it represents the regurgitant volume elevating LA pressure during systole.
Haemodynamic assessment in borderline casesExercise haemodynamics (measuring PCWP and CO during exercise) can unmask symptoms in patients with "moderate" MR who are more symptomatic than expected

Why does a tall v wave appear on the PCWP trace? The pulmonary capillary wedge pressure (PCWP) approximates LA pressure. Normally, the LA pressure trace shows a gentle a wave (atrial contraction) and a gentle v wave (venous filling during ventricular systole). In MR, the regurgitant jet adds a large volume to the LA during systole → a very prominent v wave — sometimes called a "giant v wave." This is a classic catheterisation finding of severe MR.

TestPurposeExpected Findings
BNP / NT-proBNP [8]Screening for HF; prognostic value; helps distinguish cardiac from pulmonary causes of dyspnoeaElevated in significant MR with LV volume overload. BNP < 100 rules out HF; > 400 suggests CHF [8]. NT-proBNP more specific.
CBCAnaemia assessment (can worsen MR symptoms by ↑CO → ↑regurgitant volume); haemolysis screenNcNc anaemia of chronic disease; schistocytes if mechanical valve haemolysis; leucocytosis in IE
RFTCardiorenal syndrome assessment; pre-operative baseline↑Creatinine in low-output states; hyponatraemia in severe HF [8]
LFTHepatic congestion assessment (if RV failure)↑transaminases, ↑bilirubin if congestive hepatopathy
Serial troponin (TnT/TnI) [8]Rule out MI as cause (ischaemic MR); myocardial injury assessmentElevated in acute MI causing papillary muscle dysfunction/rupture
ESR / CRPIf IE suspectedElevated in IE, but non-specific
Blood culturesIf IE suspected — at least 3 sets at different sites to demonstrate persistent bacteraemia [3]Positive with typical organisms (S. aureus, Strep viridans, Enterococci, HACEK)
TFTThyrotoxicosis can cause high-output HF and AF → worsening MRHyperthyroid state may precipitate decompensation
Rheumatic markers (ASO, anti-DNase B)If acute rheumatic fever suspected as aetiology in young patientsMay be elevated in recent streptococcal infection

InvestigationIndicationKey Findings
Exercise stress echocardiographyAsymptomatic severe MR — to unmask symptoms, exercise-induced pulmonary HTN, or ↓LVEF with exercisePASP > 60 mmHg on exercise, new regional wall motion abnormalities, symptoms with exercise = triggers for intervention
Cardiac MRI (CMR)When echo is non-diagnostic or discordant; gold standard for LV volumes and LVEF; tissue characterisationAccurate LVEDV, LVESV, LVEF calculation; quantification of regurgitant volume by comparing LV and RV stroke volumes; late gadolinium enhancement (fibrosis/scar in ischaemic MR, myocarditis)
CT coronary angiographyPre-operative assessment of coronary anatomy if catheterisation is contraindicated or in low-risk patientsRules out significant CAD before valve surgery; also provides annular and valve calcification assessment
Holter monitoringPalpitations, suspected arrhythmiaAF paroxysms, ventricular arrhythmias (especially in MVP)

Cardiac MRI — The Emerging Gold Standard

CMR is increasingly recognised as the reference standard for LV volume and EF quantification — more accurate than echo because it is not dependent on geometric assumptions. When echo results are equivocal (especially borderline LVEF values around the critical 60% threshold), CMR can provide definitive measurements. It also allows regurgitant volume quantification by comparing RV and LV stroke volumes (the difference = regurgitant volume, assuming no other valvular lesions).


QuestionPrimary InvestigationWhat You're Looking For
Is MR present?TTE with colour DopplerRegurgitant jet from LV → LA during systole
How severe is it?TTE: EROA, RVol, vena contracta, pulmonary vein flowEROA > 40 mm², RVol > 60 mL = severe primary MR [1]
What's causing it?TTE/TEE: valve morphology, leaflet motion, LV geometryProlapse/flail (MVP), thickened/restricted leaflets (RHD), vegetations (IE), tethered leaflets with annular dilation (ischaemic)
How is the LV coping?TTE: LVEF, LVESD; CMR if equivocalLVEF < 60% or LVESD ≥ 40 mm = LV decompensation — surgery indicated even if asymptomatic
Is there pulmonary HTN?TTE: TR jet velocity → PASPPASP > 50 mmHg at rest = significant pulmonary HTN
Is there concomitant CAD?Coronary angiography (catheterisation or CTA)Stenosis ≥ 70% in any major vessel → concomitant CABG at time of MV surgery
Are there complications?ECG (AF, conduction defects), BNP, RFT, LFTAF, HF biomarkers, cardiorenal syndrome, hepatic congestion

The senior notes provide a useful general framework for surgical indications across all valve lesions:

General indications for valvular replacement: [3]

  • Symptomatic (HF) despite optimal medical therapy
  • Asymptomatic, but severe disease defined by:
    • Severe stenosis/regurgitation by ECHO criteria
    • LV dilatation: LV end-systolic diameter
    • LV systolic dysfunction: impaired LVEF < 50% (note: for MR specifically, the threshold is LVEF < 60%)
    • Complications, e.g. new-onset AF, pulmonary HTN
  • Infective endocarditis despite optimal medical therapy

High Yield Summary — Diagnosis of MR

Diagnostic confirmation: TTE with colour Doppler is the first-line investigation.

Severity grading — EROA is the most recommended tool [1]:

  • Severe primary MR: EROA ≥ 40 mm², RVol ≥ 60 mL [1]
  • Severe secondary MR: EROA ≥ 20 mm², RVol ≥ 30 mL (ESC 2021)
  • Supporting signs of severity: vena contracta ≥ 7 mm, pulmonary vein systolic flow reversal, flail leaflet/ruptured papillary muscle

Investigations: ECG (AF, P mitrale, LVH) [2][3]; CXR (LA + LV enlargement, pulmonary congestion — LV enlargement distinguishes MR from MS on CXR) [2]; Echo (LV dilatation/function, severity of regurgitation, underlying valvular defects) [2]; cardiac catheterisation not routine — mainly for coronary assessment pre-surgery [2]

Key LV function thresholds in MR: LVEF < 60% and LVESD ≥ 40 mm = LV decompensation → indication for surgery even if asymptomatic

TEE indications: prosthetic valve, poor TTE window, IE suspected, pre-op planning, intra-operative


Active Recall - Diagnosis of Mitral Regurgitation

References

[1] Lecture slides: Cardiac Surgery Tutorial_Prof. D Chan.pdf (p38, p39, p43, p46) [2] Senior notes: Ryan Ho Cardiology.pdf (p155, p156, p157) [3] Senior notes: Maksim Medicine Notes.pdf (p35, p37) [4] Senior notes: Ryan Ho Cardiology.pdf (p157 — MVP section) [8] Senior notes: Maksim Medicine Notes.pdf (p18 — HF investigations, BNP) [10] Senior notes: Maksim Medicine Notes.pdf (p6 — echocardiography, TTE vs TEE)

Management of Mitral Regurgitation

Before diving into specifics, understand the fundamental management philosophy for MR — it is different from most other valve lesions:

  1. No medication can fix MR [1]. Unlike aortic stenosis (where no medical therapy alters the valve) or heart failure (where GDMT prolongs life), there is no drug that reduces or cures the regurgitant leak itself. Medical therapy in MR is purely supportive — it manages symptoms and haemodynamic consequences while buying time for surgery or palliation.

  2. Surgery is the only method to address the underlying condition [2]. The question is never whether to operate, but when — because operating too late means irreversible LV damage has already occurred, while operating too early exposes a potentially stable patient to surgical risk.

  3. Indication for surgery: severe valve problem with symptom or ventricular dysfunction [1]. This simple rule from the lecture slides captures the essence of the surgical indication.

  4. Surgery should be done early to avoid development of irreversible ↓LV function [2]. By the time a patient with MR is symptomatic, the LV may already be damaged. The goal is to intervene before the "point of no return."

The Fundamental Principle

No medication fixes MR [1]. Don't fall into the trap of thinking ACE inhibitors or beta-blockers "treat" MR — they treat the HF consequences of MR or concomitant hypertension. The leak itself can only be fixed mechanically (surgery or transcatheter intervention).



2. Acute MR — Emergency Management

Acute MR (from papillary muscle rupture, chordal rupture, leaflet perforation from IE, or prosthetic valve failure) is a haemodynamic emergency with high mortality if not surgically corrected.

The goal of medical therapy in acute MR is to bridge to emergency surgery — NOT to be the definitive treatment. The aim is to:

  • ↓Pulmonary oedema (↓preload)
  • ↑Forward cardiac output (↓afterload → diverts blood forward through the aorta rather than backward through the incompetent mitral valve)
  • Support haemodynamics if in cardiogenic shock
InterventionMechanismDosing/Notes
IV diuretics (frusemide) [2]↓Acute pulmonary oedema (APO) by ↓intravascular volume → ↓preload → ↓LA/pulmonary venous pressureIV frusemide 40–80 mg bolus; titrate to urine output
IV vasodilators (sodium nitroprusside) [2]↓Afterload → ↓impedance to forward flow → more blood exits through the aorta, less regurgitates into the LA → ↓regurgitant fraction + ↑effective CONitroprusside 0.3–5 μg/kg/min IV infusion. Contraindicated in hypotension. Requires arterial line monitoring.
IV GTN (nitroglycerin)Predominantly venodilator → ↓preload; some ↓afterload at higher doses10–200 μg/min IV. Useful if SBP adequate.
Intra-aortic balloon pump (IABP)Counterpulsation: inflates in diastole (↑coronary perfusion), deflates in systole (↓afterload → ↓regurgitant fraction). The most effective non-surgical method to rapidly ↑forward CO and ↓MR.Inserted percutaneously via femoral artery. Bridge to surgery.
Inotropes (dobutamine, milrinone)↑Contractility → ↑forward CO. Milrinone also has vasodilatory properties (phosphodiesterase-3 inhibitor = "inodilator").If cardiogenic shock with ↓BP. Dobutamine 2–20 μg/kg/min.
Intubation/mechanical ventilationPositive pressure ventilation ↓preload (↑intrathoracic pressure → ↓venous return) and ↓work of breathingIf respiratory failure, exhaustion, refractory hypoxia

Why does ↓afterload help in MR? In MR, blood takes the path of least resistance. The LA is a low-pressure chamber, so without intervention, a large fraction of each stroke volume flows backward into the LA. By reducing systemic vascular resistance (afterload), you make the aortic outflow pathway "easier" — more blood goes forward through the aorta, less goes backward. This is the opposite of what you'd do in aortic stenosis (where ↓afterload is dangerous because the fixed obstruction means ↓SVR → ↓coronary perfusion).

Acute severe MR requires emergency surgery — either repair or replacement, depending on the pathology:

CauseTypical Surgical Approach
Papillary muscle rupture (post-MI)MV replacement (the necrotic muscle base is not suitable for repair) ± CABG
Chordal rupture (degenerative)MV repair (neo-chordae placement, leaflet resection)
IE with leaflet destructionDebridement + repair if feasible; replacement if extensive destruction
Prosthetic valve failureRe-do valve replacement

3. Chronic Primary MR — Definitive Management

Medical therapy in chronic MR does NOT alter disease progression or reduce regurgitation [1][2]. Its roles are limited to:

IndicationTreatmentRationale
AF: anticoagulation, rate control [3]Warfarin (target INR 2–3) + rate control with digoxin, beta-blocker, or non-DHP CCBAF → ↓atrial contribution to LV filling + risk of LA thrombus → systemic embolism. Rate control maintains adequate diastolic filling time.
Symptomatic HFTreat underlying HF if LVEF < 60% [2]: ACEI/ARB, diuretics, beta-blockersVolume overload management. But this should prompt urgent consideration of surgery, not prolonged medical therapy.
HypertensionVasodilators only otherwise indicated for HTN [2]: ACEI/ARB/CCB↓Afterload → ↓regurgitant fraction, but this is a secondary benefit. There is NO indication for vasodilator therapy in normotensive asymptomatic MR — unlike in AR where vasodilators were historically used (now also not recommended in asymptomatic AR).
IE prophylaxisOnly in high-risk groups (prior IE, prosthetic valve) undergoing dental proceduresRoutine antibiotic prophylaxis is NOT recommended [3]. Only for high-risk groups.

Common Exam Mistake

Students often think ACE inhibitors are "treatment" for MR. They are NOT — there is no medication for MR [1]. ACEIs/ARBs are only used if there is concomitant HTN or HF with ↓LVEF. Do not prescribe vasodilators for normotensive, asymptomatic, compensated MR.

Surgery should be done early to avoid development of irreversible ↓LV function [2].

Severe primary MR — Surgical indications (2020 ACC/AHA / 2021 ESC guidelines):

ScenarioRecommendationRationale
Symptomatic severe primary MRSurgery indicated [1][2]Any symptom (dyspnoea, fatigue, ↓exercise tolerance) in severe primary MR = operate. The valve is broken and the patient is suffering.
Asymptomatic severe primary MR with LV dysfunctionSurgery indicated if LVEF < 60% [2]LVEF cutoff is higher for MR because MR is a volume loading condition → LVEF should be high [2]. LVEF < 60% means intrinsic LV contractility has already declined despite the low-impedance "pop-off" valve into the LA.
Asymptomatic severe primary MR with LV dilationSurgery indicated if LVESD ≥ 40 mm [2]LVESD reflects end-systolic volume — a measure of how much residual blood remains after contraction. If the LV cannot empty adequately (LVESD ≥ 40 mm), it is failing.
Asymptomatic severe primary MR with complicationsSurgery indicated if new-onset AF or pulmonary HTN (PASP > 50 mmHg at rest) [2][3]New AF: LA has dilated to the point of electrical instability — the disease is progressing. Pulmonary HTN: back-pressure is now affecting the pulmonary vasculature — delayed surgery risks irreversible pulmonary vascular disease.
Asymptomatic severe primary MR, normal LV function, no triggersWatchful waiting with echo every 6 months [2]. Consider early surgery if high likelihood of durable repair at an experienced centre (2020 ACC/AHA Class IIa)."Severe primary MR except if asymptomatic + normal LV systolic function (LVEF ≥ 60%, LVESD < 40 mm) + no other indications for surgery (new-onset AF, pHTN)" [2] — these patients can be safely monitored.

Summary of triggers for surgery in asymptomatic severe primary MR:

Symptoms → Operate. LVEF < 60% → Operate. LVESD ≥ 40 mm → Operate. New AF → Operate. PASP > 50 mmHg → Operate. None of the above → Watch and wait (but consider early repair at expert centre).

3.3 Surgical Techniques — Repair vs. Replacement

Choice: repair is usually preferred to replacement [2].

MV repair: reconstruction of parts of valve responsible for regurgitation [2]

AspectDetails
PrincipleReconstruct the valve to restore competent leaflet coaptation while preserving native valve tissue
AdvantagesPreserve chordae and papillary muscle function (important for LV function) [2]; avoid long-term anticoagulation use (only require short-term warfarinisation) [2]; lower operative mortality; lower rate of endocarditis vs. prosthetic valve; better LV function preservation
Mortality2–4% [2]
Preferred inGenerally preferred for younger patients with myxomatous involvement of mitral valve [2]
Best suited forIsolated P2 prolapse/flail (most common and most "repairable" lesion); limited anterior leaflet pathology; annular dilation without extensive leaflet disease
TechniquesLeaflet resection (triangular or quadrangular resection of prolapsing segment); neo-chordae (artificial ePTFE chordae to replace ruptured chordae); annuloplasty ring (restores annular geometry, prevents further dilation — used in almost all repairs); edge-to-edge repair (Alfieri stitch — creates a "double-orifice" valve)

Why is preserving the chordae and papillary muscles so important? The chordae and papillary muscles are not just passive tethers — they actively contribute to LV contraction and geometry. The chordae transmit papillary muscle tension to the annulus during systole, contributing to systolic annular narrowing and longitudinal shortening. When these structures are excised (as in MVR without chordal preservation), LV function drops significantly. This is why "preserving chordae and papillary muscle function is important for LV function" [2].

MV replacement: total removal and replacement by prosthetic valve [2]

AspectDetails
PrincipleExcise the diseased valve and implant a prosthetic valve
Mortality5–7% [2] — higher than repair because of greater surgical complexity, more extensive tissue excision, and prosthesis-related complications
Preferred inGenerally preferred for older patients with more extensive valve pathology [2]; heavily calcified rheumatic valves; failed previous repair
Chordal preservationModern technique aims to preserve the posterior leaflet chordae even during replacement — mitigates the loss of LV function
Choice of Prosthetic Valve: Mechanical vs. Bioprosthetic
FeatureMechanical ValveBioprosthetic Valve
DurabilityEssentially lifelong (> 25–30 years)Limited: 10–15 years (degenerates faster in younger patients and in the mitral position due to higher closure pressures)
AnticoagulationLifelong warfarin required (INR 2.5–3.5 for mechanical mitral valve; higher than aortic position)Short-term warfarin only (3–6 months), then aspirin alone
Major riskBleeding from anticoagulation; valve thrombosis if sub-therapeutic INRStructural valve deterioration requiring reoperation
Best forYounger patients (< 65–70 y) who can comply with lifelong warfarin and INR monitoringOlder patients (≥ 65–70 y), patients with contraindications to anticoagulation, women of childbearing age (warfarin is teratogenic)
SoundAudible metallic click on auscultationSilent

Why is the INR target higher for a mechanical mitral valve than a mechanical aortic valve? The mitral position experiences lower flow velocities during diastolic filling (compared to the aortic position during systolic ejection). This lower velocity creates more stasis → higher thrombogenicity → requires more aggressive anticoagulation (INR 2.5–3.5 vs. 2.0–3.0 for aortic).

Repair vs. Replacement — The Bottom Line

Repair is preferred whenever feasible because it: (1) preserves the subvalvular apparatus (→ better LV function), (2) avoids lifelong anticoagulation, (3) has lower operative mortality (2–4% vs. 5–7%), and (4) has lower risk of prosthesis-related complications (thrombosis, haemolysis, endocarditis). The main limitation is that not all valves are repairable — rheumatic, heavily calcified, or extensively destroyed valves may require replacement.


4. Chronic Secondary (Functional) MR — Management

Secondary MR is fundamentally different from primary MR — the valve is normal but the ventricle is sick. Therefore, the management focuses primarily on treating the underlying ventricular disease.

This is the first-line approach for secondary MR. Treating the underlying LV dysfunction may reduce MR severity by:

  • ↓LV volume → ↓annular dilation → improved coaptation
  • ↓Afterload → ↑forward flow → ↓regurgitant fraction
  • Reverse remodelling → restoration of LV geometry → improved papillary muscle alignment
Drug ClassMechanism in MR ContextKey Agents
ACEi/ARB/ARNI↓Afterload + neurohormonal blockade → ↓LV remodelling → ↓annular dilation → ↓MR. Sacubitril/valsartan (ARNI) superior to ACEi alone in HFrEF.Ramipril, valsartan, sacubitril/valsartan
Beta-blockers↓HR → ↑diastolic filling time + anti-remodelling. Caveat: BB can worsen regurgitant fraction due to prolonged diastolic time [11] — but overall mortality benefit in HFrEF outweighs this.Bisoprolol, carvedilol, metoprolol succinate
MRA↓Aldosterone-mediated fibrosis + ↓Na/water retention → ↓LV remodellingSpironolactone, eplerenone
SGLT2 inhibitors↓Preload (glycosuria → osmotic diuresis) + cardioprotective effects independent of diabetes; reduce HF hospitalisations and CV death (DAPA-HF, EMPEROR-Reduced)Dapagliflozin, empagliflozin
Diuretics↓Preload → ↓pulmonary congestion, ↓LV volume → may ↓MRFrusemide, bumetanide
Cardiac resynchronisation therapy (CRT)In patients with LBBB + LVEF ≤ 35%: biventricular pacing resynchronises LV contraction → ↓functional MR by improving papillary muscle coordination and ↓LV dyssynchronyCRT-D or CRT-P

Severe secondary MR: surgery only when symptomatic (NYHA III–IV) or concomitant CABG/AVR [2].

This is much more restrictive than primary MR because:

  • The underlying LV disease persists even after valve surgery → outcomes are worse
  • Trials (CTSN trials) showed limited survival benefit of MV repair/replacement for ischaemic MR in many patients
  • Medical optimisation alone may sufficiently reduce functional MR
InterventionIndicationDetails
MV repair + annuloplasty ring ± CABGSecondary MR with concomitant CABG indication; NYHA III–IV despite GDMTUndersized annuloplasty ring to overcorrect the annular dilation. However, CTSN trial showed significant recurrence of MR after repair in ischaemic MR (up to 59% at 2 years).
MV replacement (with chordal preservation) ± CABGWhen repair is not feasible or expected to be durable; NYHA III–IV despite GDMTCTSN trial showed no difference in LV reverse remodelling at 2 years between repair and replacement for severe ischaemic MR — replacement had lower MR recurrence.
Transcatheter edge-to-edge repair (TEER / MitraClip)High surgical risk patients with secondary MR, NYHA III–IV despite optimal GDMTMitraClip clips the anterior and posterior leaflets together, creating a double-orifice valve (based on the Alfieri stitch concept). COAPT trial showed significant reduction in HF hospitalisations and mortality in carefully selected patients with functional MR. MITRA-FR trial showed no benefit — highlighting the importance of patient selection.
CABG aloneModerate secondary MR with CAD amenable to revascularisationRevascularisation may improve papillary muscle function → ↓MR. Adding MV repair to CABG for moderate ischaemic MR did not improve outcomes (RIME trial).

ScenarioManagement
Asymptomatic MVP without MRReassurance. No treatment needed. No activity restriction. Echo follow-up every 3–5 years.
MVP with palpitationsTreat arrhythmias [3]. Beta-blockers for symptomatic premature ventricular/atrial complexes.
MVP with atypical chest painTreat chest pain: beta-blockers [3]. Mechanism: ↓HR → ↓papillary muscle stress → ↓ischaemia.
MVP with significant MRManage as for primary MR (see above). MV repair is highly favourable for MVP because the myxomatous valve tissue is pliable and repairable.
MVP with stroke/TIAAntiplatelet therapy (aspirin). Anticoagulation if AF or recurrent events.

6. Special Considerations

SituationAnticoagulation
Native valve MR without AFNOT indicated
Native valve MR with AFWarfarin (INR 2–3) or DOAC. CHA₂DS₂-VASc score guides decision (most patients with valvular AF warrant anticoagulation). Note: DOACs are acceptable in non-MS, non-mechanical valve AF.
Mechanical mitral valveLifelong warfarin (INR 2.5–3.5). DOACs are CONTRAINDICATED (RE-ALIGN trial showed increased thrombosis and bleeding with dabigatran in mechanical valves).
Bioprosthetic mitral valveWarfarin for 3–6 months post-surgery (INR 2–3), then aspirin alone if no AF
Post-MV repairShort-term warfarinisation [2], typically 3 months, then aspirin

  • MR is generally well-tolerated in pregnancy (unlike MS). The ↓SVR of pregnancy → ↓afterload → ↓regurgitant fraction → may actually improve symptoms.
  • Medical management: diuretics if symptomatic (avoid ACEi/ARB — teratogenic); beta-blockers safe.
  • If prosthetic valve: mechanical valve + warfarin is problematic (warfarin is teratogenic in 1st trimester; heparin bridging protocols are complex and carry risk). Bioprosthetic valve avoids this issue but has limited durability.

Routine antibiotic prophylaxis is NOT recommended [3].

Only for high-risk groups [3]:

  • Prosthetic valve replacement/repair
  • Previous IE
  • Congenital heart disease: unrepaired cyanotic CHD, repaired with residual defects, completely repaired within the first 6 months

For dental procedures: amoxicillin 2g PO / ampicillin IV; single dose 30–60 min before procedure; clindamycin 600 mg PO/IV if allergic to penicillin [3].


AspectDetails
ApproachMedian sternotomy (traditional); right mini-thoracotomy (minimally invasive); robotic-assisted (available at QMH in HK)
Sternotomy recoveryTakes ~10 weeks for sternal bone to heal → no weight-bearing upper body exercise; larger wound; risk of sternal wound infection
Cardiopulmonary bypassRequired for all open MV surgery — heart arrested, blood oxygenated externally
General complicationsCVA, severe infection, bleeding, multi-organ failure
Specific cardiac complicationsHeart block (particularly with posterior annuloplasty near the conduction system), heart failure, perioperative MI
OutcomeMortality 2–4% for MV repair, 5–7% for MVR [2]. Progressive ↓symptoms and ↑heart function ~3 months post-surgery

High Yield Summary — Management of MR

No medication fixes MR [1]. Surgery is the definitive treatment.

Acute MR: IV diuretics + IV vasodilators (nitroprusside) [2] → ↓preload + ↓afterload → bridge to emergency surgery. IABP if unstable.

Chronic Primary MR — Surgical indications:

  • Symptomatic severe primary MR → surgery
  • Asymptomatic: operate if LVEF < 60%, LVESD ≥ 40 mm, new-onset AF, or PASP > 50 mmHg [2]
  • If none of the above (LVEF ≥ 60%, LVESD < 40 mm, no AF/pHTN) → watchful waiting [2]

Repair vs. Replacement:

  • Repair preferred (mortality 2–4%) — preserves chordae/papillary muscle function, avoids long-term anticoagulation [2]
  • Replacement (mortality 5–7%) — for older patients with extensive pathology [2]

Chronic Secondary MR: Optimise GDMT first → surgery only if NYHA III–IV despite optimal Mx, or concomitant CABG/AVR [2]. TEER (MitraClip) for high surgical risk.

Anticoagulation: Mechanical mitral valve = lifelong warfarin INR 2.5–3.5. Bioprosthetic = short-term warfarin then aspirin. DOACs contraindicated in mechanical valves.


Active Recall - Management of Mitral Regurgitation

References

[1] Lecture slides: Cardiac Surgery Tutorial_Prof. D Chan.pdf (p36, p38, p39, p43, p46) [2] Senior notes: Ryan Ho Cardiology.pdf (p155, p157) [3] Senior notes: Maksim Medicine Notes.pdf (p35, p37, p39) [4] Senior notes: Ryan Ho Cardiology.pdf (p157 — MVP section) [11] Senior notes: Ryan Ho Cardiology.pdf (p154, p161 — surgical approach and complications; BB and regurgitant fraction)

Complications of Mitral Regurgitation

Complications of MR can be thought of as the downstream consequences of the core haemodynamic disturbance: blood leaking backward from the LV into the LA during systole. Every complication traces back to one of three fundamental problems — volume overload of the LA, volume overload of the LV, or reduced forward cardiac output. Additionally, there are complications of the underlying aetiology itself and complications related to surgical intervention.

Let's work through each systematically, linking every complication to its pathophysiological origin.


The natural history of untreated severe MR is a progressive march through the following complications. The sequence is predictable and directly mirrors the pathophysiology discussed earlier:


2. Detailed Complications

AF occurs in approximately 1/3 of patients with severe chronic MR [2].

Pathophysiology from first principles:

  • Chronic MR → regurgitant volume enters the LA during every systole → LA volume overload → LA dilation
  • LA dilation causes mechanical stretch of atrial myocytes → structural remodelling (fibrosis of the atrial wall) + electrical remodelling (shortened refractoriness, altered conduction velocities)
  • This creates the substrate (patchy fibrosis → areas of slow conduction) and triggers (stretched myocytes → ectopic foci, especially from the pulmonary veins) for re-entrant circuits → AF

Why does AF matter so much in MR?

  1. Loss of atrial contraction → loss of the "atrial kick" (normally contributes ~15–25% of LV filling). In a heart already compromised by MR, this loss of the atrial contribution precipitates decompensation
  2. Rapid ventricular rate → ↓diastolic filling time → ↓forward CO + ↑LA pressure → acute pulmonary congestion
  3. Blood stasis in the dilated LA → thromboembolism risk (see below)
  4. New-onset AF is an indication for surgery even in asymptomatic patients [2][3] — it signals that LA remodelling has progressed to the point of electrical instability

Management: AF: anticoagulation, rate control [3]. Warfarin (INR 2–3) or DOAC for stroke prevention. Rate control with beta-blockers, digoxin, or non-DHP CCB.

Embolic stroke is listed as a specific complication of MR and MVP [3].

Pathophysiology:

  • LA dilation + loss of effective atrial contraction (AF or even in sinus rhythm with a severely dilated, "stunned" LA) → blood stasis in the LA, especially in the left atrial appendage (LAA)
  • Stasis → thrombus formation (Virchow's triad: stasis + endothelial injury + hypercoagulability)
  • Thrombus embolisation → systemic embolism, most devastatingly to the brain (embolic stroke), but also to kidneys (renal infarction), spleen (splenic infarction), mesenteric vessels (mesenteric ischaemia), and peripheral arteries (acute limb ischaemia)

In MVP specifically: Embolism due to microthrombus formation behind redundant valve tissue [4]. The redundant, billowing leaflet creates a "dead space" on its atrial surface where flow is turbulent and stagnant → platelet-fibrin deposition → microthrombi → embolic events.

Clinical significance: Stroke in a young patient with MR or MVP should always prompt echocardiography (TTE/TEE) to look for LA thrombus, severe LA dilation, and valve pathology.

This is the most important complication of chronic MR because it determines prognosis and surgical timing.

Pathophysiology — the vicious cycle:

  • Chronic MR → LV volume overload → eccentric LV hypertrophy (sarcomere addition in series → LV dilation)
  • Initially compensatory: the Frank-Starling mechanism maintains stroke volume
  • Over years, the chronically overloaded myocardium undergoes adverse remodelling: myocyte apoptosis, interstitial fibrosis, neurohumoral activation (RAAS, sympathetic nervous system)
  • This leads to intrinsic myocardial contractile dysfunction (↓LVEF)
  • Once LV systolic function declines, the heart enters a decompensated phase: ↓forward CO + ↑LV filling pressures → clinical heart failure

Once severe, MR is NOT benign: patients develop symptoms at 10%/year, AF in 1/3 [2].

90% of asymptomatic patients with normal LVEF will have surgery at 10 years [2] — meaning that even initially "benign-looking" severe MR progresses inevitably.

The Irreversibility Problem

Surgery should be done early to avoid development of irreversible ↓LV function [2]. The LV dysfunction in MR is initially reversible — if the volume overload is removed (by fixing the valve), the LV can recover. But beyond a certain point (LVEF < 30–40%, extensive fibrosis), the damage becomes permanent. This is why the surgical threshold is LVEF < 60% or LVESD ≥ 40 mm — to intervene BEFORE irreversibility sets in.

Pulmonary hypertension only occurs late when the LV fails due to volume overload [2].

Pathophysiology — two components:

ComponentMechanismReversibility
Passive (postcapillary)↑LA pressure → transmitted backward to pulmonary veins → ↑pulmonary venous pressure → ↑pulmonary capillary pressure → ↑PAPPotentially reversible if LA pressure is normalised (by fixing the valve)
Reactive (precapillary component superimposed)Chronic ↑pulmonary venous pressure → reactive vasoconstriction of pulmonary arterioles + structural remodelling (medial hypertrophy, intimal fibrosis of pulmonary arterioles) → fixed ↑pulmonary vascular resistance (PVR)May become irreversible if long-standing → surgery may not fully reverse the pHTN

Clinical signs of pulmonary hypertension [3]:

  • Elevated JVP with systolic "v" waves (functional TR)
  • Parasternal heave (RV pressure overload)
  • Parasternal thrills (functional TR)
  • Loud P2
  • Pansystolic murmur of TR
  • Graham-Steell murmur of PR — PR murmur, associated with loud P2, indicating severe MS [3] (though it can occur in any cause of severe pulmonary HTN, including advanced MR)

Why it matters: New-onset pulmonary hypertension (sPAP > 50 mmHg) is an indication for surgery [3] — it signals that the backward pressure is now remodelling the pulmonary vasculature. Delay risks irreversible pulmonary vascular disease.

Right heart failure is the end-stage complication of chronic MR, representing the final common pathway of untreated disease.

Pathophysiology chain: Chronic MR → LV failure → ↑LA pressure → pulmonary venous HTN → pulmonary arterial HTN → ↑RV afterload → RV pressure overload → RV hypertrophy → eventually RV dilation and failure

Clinical features of RV failure [2][3]:

  • Ankle oedema (if RVF) [2] — hydrostatic back-pressure in systemic veins → transudation into interstitial space, gravitationally dependent
  • Elevated JVP — systemic venous congestion directly reflected by ↑RA pressure
  • Hepatomegaly ± pulsatile liver — hepatic venous congestion → hepatic enlargement. If TR is present (functional TR from RV dilation), the liver pulsates with each systolic regurgitant wave.
  • Ascites — portal venous congestion → transudation into peritoneal cavity
  • Functional TR — RV dilation → tricuspid annulus dilation → TR → further systemic venous congestion (a self-perpetuating cycle)

MR increases the risk of IE because the regurgitant jet creates endothelial damage on the atrial surface of the mitral valve and the LA wall.

Pathophysiology:

  • The high-velocity regurgitant jet impacts the atrial surface of the valve leaflets and the adjacent LA endocardium
  • This jet lesion creates areas of endothelial denudation → deposition of platelets and fibrin → non-bacterial thrombotic endocarditis (NBTE) — a sterile "landing pad"
  • During transient bacteraemia (dental procedures, invasive procedures, even daily activities like tooth-brushing), circulating bacteria adhere to this fibrin-platelet nidus → colonisation → vegetation formation → IE

Valve involvement in IE: MV >> AV > TV > PV [3] — the mitral valve is the most commonly affected valve overall.

Infective endocarditis despite optimal medical therapy is an indication for surgery [3].

IE complicating MR can worsen the regurgitation through:

  • Leaflet destruction/perforation
  • Chordal rupture (vegetations weaken chordae)
  • Abscess formation at the annulus

This creates a dangerous positive feedback loop: MR → IE → worsened MR → acute decompensation.

Ortner's syndrome: LA enlargement → compression of left recurrent laryngeal nerve (RLN) → hoarseness of voice [3].

Pathophysiology from first principles:

  • The left RLN loops under the aortic arch and passes between the aorta and the pulmonary artery before ascending to the larynx
  • Massive LA dilation (as seen in severe chronic MR, MS, or any cause of giant LA) pushes upward against the left main bronchus and the space between the aorta and pulmonary artery
  • This compresses the left RLN → left vocal cord paralysis → hoarseness

This is more classically associated with MS (where LA dilation is typically more extreme), but can occur in severe chronic MR with a giant LA. It is rarely the presenting complaint but can be an exam question.

Acute mechanical complications from MI that cause MR are specific and high-mortality [1]:

  • MR from rupture of papillary head [1] — typically occurs 2–7 days post-MI (when the necrotic tissue is weakest and granulation tissue has not yet formed). The posteromedial papillary muscle is most vulnerable (single blood supply from the PDA/RCA).
  • This is high risk for mortality [1].
  • Presentation: sudden haemodynamic collapse with flash pulmonary oedema, often with a surprisingly soft murmur (because rapid LV-LA pressure equilibration reduces the murmur intensity)
  • Other acute mechanical complications listed alongside acute MR [1]:
    • Shock from large area (~40%) myocardium involved
    • VSD from transmural infarct and rupture of muscular septum
    • Tamponade from free wall rupture, myocarditis, pericarditis, iatrogenic

Post-MI Mechanical Complications — All High Mortality

Anyone of these is high risk for mortality [1]. Post-MI acute MR from papillary muscle rupture has mortality approaching 50% without surgery and up to 20–25% even with emergency surgery. The key is rapid diagnosis (bedside echo) and immediate surgical intervention.


MVP has its own set of complications, some overlapping with general MR complications and some unique:

ComplicationMechanism
Progression to severe MR [3]Progressive myxomatous degeneration → leaflet elongation and chordal stretching → worsening prolapse → increasing MR. Can be chronic (gradual) or acute (chordal rupture).
Embolic stroke [3]Embolism due to microthrombus formation behind redundant valve tissue [4] — the billowing leaflet creates turbulent, stagnant flow on its atrial surface → platelet-fibrin deposition → microemboli
Endocarditis [3]Abnormal valve surface → predisposition to bacterial colonisation during bacteraemia
Arrhythmia (prolonged QT) [3]Arrhythmias: atrial or ventricular [4]. Mechanism: papillary muscle traction → myocardial ischaemia → arrhythmogenic substrate. Prolonged QT may predispose to torsades de pointes.
Sudden cardiac deathRare but recognised — thought to be due to ventricular arrhythmias, possibly related to papillary muscle traction, myocardial fibrosis at leaflet insertion points, or associated prolonged QT

4. Complications of Surgical Intervention

Surgical treatment of MR — while definitive — carries its own set of complications [2][11]:

ComplicationMechanism
CVA (stroke)Air embolism during cardiopulmonary bypass; thromboembolism from manipulation of the aorta or LA; atrial fibrillation post-operatively
Severe infectionSternal wound infection (especially after median sternotomy); mediastinitis; prosthetic valve endocarditis
BleedingHeparinisation during cardiopulmonary bypass → coagulopathy; surgical bleeding from suture lines; post-operative anticoagulation for mechanical valve
Multi-organ failureProlonged cardiopulmonary bypass → systemic inflammatory response; low cardiac output syndrome post-operatively → end-organ ischaemia

ComplicationMechanism
Heart blockThe mitral annulus is in close proximity to the atrioventricular (AV) node and the bundle of His, especially posteriorly. Suturing an annuloplasty ring or prosthetic valve too deep posteriorly can injure the conduction system → complete heart block requiring permanent pacemaker.
Heart failurePerioperative myocardial stunning from ischaemia during aortic cross-clamping; loss of chordal/papillary muscle function (if not preserved during replacement) → post-operative LV dysfunction
Perioperative MIAir or thrombotic embolism into coronary arteries; inadequate myocardial protection during bypass; kinking of coronary arteries during surgery

ComplicationMechanical ValveBioprosthetic Valve
Thrombosis/embolismHigh risk without adequate anticoagulation → valve thrombosis (obstruction) or systemic embolism. INR 2.5–3.5 required lifelong for mitral position.Low risk; short-term anticoagulation only
BleedingFrom lifelong warfarin therapy — intracranial haemorrhage, GI bleeding, etc. Annual risk ~1–2%.Minimal (no long-term anticoagulation)
Structural valve deteriorationVirtually none (lasts > 25 years)Degenerates over 10–15 years — leaflets undergo calcification and tearing. Faster in younger patients and in the mitral position (higher closing pressures). Requires reoperation.
Prosthetic valve endocarditis~1% per year. Early ( < 12 months): coagulase-negative Staph; Late ( > 12 months): similar to native valve IE. Mortality high (up to 60%).Similar risk
HaemolysisMechanical valve → mechanical shear stress on RBCs passing through the prosthesis → chronic intravascular haemolysis. Usually subclinical but can cause anaemia. Paravalvular leak worsens haemolysis (turbulent flow through the gap).Minimal
Pannus formationTissue ingrowth over the prosthetic valve ring → gradual obstruction. Occurs more with mechanical valves.Rare
Patient-prosthesis mismatchEffective orifice area of the prosthesis too small for the patient's body surface area → residual gradient → functional stenosis. More common with smaller valve sizes.Same risk

ComplicationMechanism
Residual MRClip may not achieve adequate leaflet coaptation → persistent regurgitation requiring further intervention
Mitral stenosisClip creates a double-orifice valve → if the remaining orifice areas are too small, functional stenosis results
Clip detachmentRare — the clip can embolise or partially detach, worsening MR acutely
Vascular access complicationsLarge-bore femoral venous access + transseptal puncture → bleeding, femoral AV fistula, cardiac perforation, pericardial tamponade
Residual ASDTransseptal puncture creates an iatrogenic ASD that may not close spontaneously

When valve disease is not repairable [1]:

  • Most aortic valve disease — very difficult to repair
  • Most mitral stenosis — no normal tissue to repair
  • Some mitral regurgitation — congenital disease, too complex, or suboptimal repair

This is an important concept because it determines whether a patient receives a repair (with all its advantages) or a replacement (with the prosthesis-related complications listed above). The decision is made intraoperatively when the surgeon directly visualises the valve.


High Yield Summary — Complications of MR

Haemodynamic complications (predictable cascade):

  1. LA dilation → AF (1/3 of severe MR) [2] → thromboembolism/stroke
  2. LV volume overload → eccentric hypertrophy → LV systolic dysfunction (irreversible if delayed) [2] → HF
  3. ↑LA pressure → pulmonary HTN (late) [2] → RV failure → systemic congestion

Specific complications:

  • Ortner syndrome: LA dilation → compression of left RLN → hoarseness [3]
  • IE: regurgitant jet damages endocardium → predisposes to bacterial colonisation [3]
  • Post-MI papillary muscle rupture: high risk for mortality [1] — surgical emergency

MVP complications [3]: embolic stroke, endocarditis, arrhythmia (prolonged QT), progression to severe MR

Surgical complications: heart block, HF, perioperative MI, stroke, bleeding, infection. Prosthetic valve: thrombosis (mechanical), structural deterioration (bioprosthetic), endocarditis, haemolysis.

Key triggers for surgery (= complications that demand intervention) [2][3]: new AF, PASP > 50 mmHg, LVEF < 60%, LVESD ≥ 40 mm.


Active Recall - Complications of Mitral Regurgitation

References

[1] Lecture slides: Cardiac Surgery Tutorial_Prof. D Chan.pdf (p31, p38, p43, p46, p56) [2] Senior notes: Ryan Ho Cardiology.pdf (p155, p157) [3] Senior notes: Maksim Medicine Notes.pdf (p35, p36, p37) [4] Senior notes: Ryan Ho Cardiology.pdf (p157 — MVP complications) [11] Senior notes: Ryan Ho Cardiology.pdf (p154 — surgical approach and complications)

On this page

No Headings